Claims
- 1. An acid derivative of the formula (I)
- R.sup.1 --CON(R.sup.2)--N(R.sup.3)CO--X.sup.1 --Q--X.sup.2 --G (I)
- wherein R.sup.1 represents a group of the formula (III) ##STR2## in which T is N, and X.sup.3 is a bond or (1-4C)alkylene;
- R.sup.2 and R.sup.3, which may be the same or different, represent hydrogen, (1-4C)alkyl or ar(1-4C)alkyl;
- X.sup.1 is a bond or (1-4C)alkylene;
- Q is a group of formula (IV) ##STR3## in which Z.sup.2 is hydrogen, halogeno, (1-4C)alkyl, (1-4C)alkoxy, cyano or nitro, and
- Z.sup.3 is a group of formula X.sup.2 --G.sup.a in which X.sup.2 can have any of the values given hereinafter for X.sup.2 and G.sup.a can have any of the values given hereinafter for G, or G.sup.a has any of the values given hereinbefore for Z.sup.2 ;
- X.sup.2 is a bond, (1-4C)alkylene, or oxy(1-3C)alkylene; and
- G is a carboxy group or a pharmaceutically acceptable metabolically labile ester or amide thereof; and
- a pharmaceutically acceptable salt thereof.
- 2. An acid derivative of formula (I) as claimed in claim 1 wherein R.sup.1 represents a group of formula (III) in which T is N, and X.sup.3 is a bond, methylene or ethylene;
- R.sup.2 is hydrogen, methyl or benzyl;
- R.sup.3 is hydrogen, methyl or benzyl;
- X.sup.1 is a bond;
- Q is a group of formula IV in which Z.sup.2 is hydrogen, fluoro, chloro, methyl or methoxy, and Z.sup.3 is hydrogen or a group of formula X.sup.2 --G.sup.a in which X.sup.2 is oxymethylene and G.sup.a is carboxy, methoxycarbonyl or ethoxycarbonyl;
- X.sup.2 is oxymethylene; and
- G is carboxy, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl or t-butoxycarbonyl;
- or a pharmaceutically acceptable salt thereof.
- 3. An acid derivative of formula (I) as claimed in claim 1 wherein R.sup.1 represents a group of formula (III) in which T is N and
- X.sup.3 is a bond or (1-4C)alkylene;
- R.sup.2 is hydrogen;
- R.sup.3 is hydrogen or methyl;
- X.sup.1 is a bond;
- Q is a group of the formula (IV) in which Z.sup.2 is hydrogen and Z.sup.3 is hydrogen or a group of formula X.sup.2 --G.sup.a in which X.sup.2 is oxymethylene and G.sup.a is carboxy;
- X is oxymethylene; and
- G is carboxy, methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl;
- or a pharmaceutically acceptable salt thereof.
- 4. An acid derivative of formula (I) as claimed in claim 1 wherein R.sup.1 represents a group of formula (III) in which T is N and
- X.sup.3 is a bond;
- R.sup.2 is hydrogen;
- R.sup.3 is hydrogen or methyl;
- X.sup.1 is a bond;
- Q is a group of formula IV in which Z.sup.2 is hydrogen and Z.sup.3 is hydrogen or a group of formula X.sup.2 --G.sup.a in which X.sup.2 is oxymethylene G.sup.a is carboxy;
- X.sup.2 is oxymethylene; and
- G is carboxy, methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl;
- a pharmaceutically acceptable salt thereof.
- 5. The compound 4-[3'-(piperazin-1-ylcarbonyl)carbazolyl]2-carboxymethoxy)phenoxy acetic acid; or a pharmaceutically acceptable salt thereof.
- 6. A process for the preparation of an acid derivative of formula (I)
- R.sup.1 --CON(R.sup.2)--N(R.sup.3)CO--X.sup.1 --Q--X.sup.2 --G (I)
- or a pharmaceutically acceptable metabolically labile ester or amide thereof, or a pharmaceutically acceptable salt thereof, as claimed in claim 1 which process comprises:
- (A) for a compound of formula (I) in which G is carboxy, deprotecting a compound of formula (VI)
- R.sup.1 --CON(R.sup.2)--N(R.sup.3)CO--X.sup.1 --Q--X.sup.2 --COOG.sup.1 (VI)
- in which G.sup.1 is a carboxy protecting group;
- (B) reacting a compound of formula (IX)
- R.sup.1 --COOH (IX)
- or a reactive derivative thereof, with a compound of formula (X)
- HN(R.sup.2)--N(R.sup.3)CO--X.sup.1 --Q--X.sup.2 --G (X)
- (C) reacting a compound of formula (XI)
- R.sup.1 --CON(R.sup.2)--NHR.sup.3 (XI)
- with a compound of formula (XII)
- HOOC--X.sup.1 --Q--X.sup.2 --G (XII)
- or a reactive derivative thereof; or
- (D) for a compound of formula (I) in which X.sup.2 is a group of formula CH.sub.2 CH(NHXR.sup.4), reacting a compound of formula (XIII)
- R.sup.1 --CON(R.sup.2)--N(R.sup.3)CO--X.sup.1 --Q--X.sup.2a --G (XIII)
- in which X.sup.2a is CH.sub.2 CH(NH.sub.2), or an acid addition salt thereof, with a compound of formula (XIV)
- R.sup.4 X--U.sup.1 (XIV)
- in which U.sup.1 is a leaving atom or group;
- whereafter, optionally a compound of formula I is converted into a pharmaceutically acceptable metabolically labile ester or amide thereof, or a pharmaceutically acceptable salt thereof.
- 7. A method of inhibiting platelet aggregation in a warm-blooded mammal requiring such treatment, which comprises administering an effective amount of an acid derivative of formula (I), or a pharmaceutically acceptable metabolically labile ester or amide thereof, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-5.
- 8. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable metabolically acceptable salt thereof, as claimed in any one of claims 1-5 together with a pharmaceutically acceptable diluent or carrier.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9313285 |
Jun 1993 |
GBX |
|
Parent Case Info
This is a division of application Ser. No. 08/767,443, filed Dec. 16, 1996, U.S. Pat. No. 5,760,057, which is a divisional of application Ser. No. 08/266,375 filed Jun. 27, 1994, U.S. Pat. No. 5,612,373.
US Referenced Citations (8)
Foreign Referenced Citations (41)
Number |
Date |
Country |
74101 |
Oct 1991 |
AUX |
10403 |
Jul 1992 |
AUX |
20569 |
Jan 1993 |
AUX |
21119 |
Feb 1993 |
AUX |
20892 |
Mar 1993 |
AUX |
27062 |
Apr 1993 |
AUX |
41201 |
Dec 1993 |
AUX |
2008116 |
Sep 1990 |
CAX |
2037153 |
Sep 1991 |
CAX |
2060661 |
Sep 1992 |
CAX |
2093770 |
Oct 1993 |
CAX |
2094773 |
Oct 1993 |
CAX |
0007648 |
Jun 1980 |
EPX |
0116729 |
Aug 1984 |
EPX |
0136745 |
Oct 1985 |
EPX |
0475506 |
Mar 1992 |
EPX |
0478328 |
Apr 1992 |
EPX |
0479481 |
Apr 1992 |
EPX |
0478363 |
Apr 1992 |
EPX |
0478362 |
Apr 1992 |
EPX |
0512829 |
Nov 1992 |
EPX |
0512831 |
Nov 1992 |
EPX |
0513675 |
Nov 1992 |
EPX |
0529858 |
Mar 1993 |
EPX |
07867 |
Apr 1993 |
EPX |
0539343 |
Apr 1993 |
EPX |
0540334 |
May 1993 |
EPX |
0560730 |
Sep 1993 |
EPX |
05562 |
May 1991 |
WOX |
13552 |
Aug 1992 |
WOX |
18117 |
Oct 1992 |
WOX |
17196 |
Oct 1992 |
WOX |
08181 |
Apr 1993 |
WOX |
01874 |
Apr 1993 |
WOX |
10091 |
May 1993 |
WOX |
12074 |
Jun 1993 |
WOX |
14077 |
Jul 1993 |
WOX |
16038 |
Aug 1993 |
WOX |
19046 |
Sep 1993 |
WOX |
22303 |
Nov 1993 |
WOX |
01396 |
Jan 1994 |
WOX |
Non-Patent Literature Citations (2)
Entry |
Alig et al., "Low Molecular Weight, non-peptide Fibrinogen Receptor Antagonists," J. Med. Chem., 1992, 35, 4393-4407. |
Hartman et al., "Non-peptide Fibrinogen Receptor Antagonists 1. Discovery and Design of Exosite Inhibitors," J. Med. Chem., 1992, 35, 4640-4642. |
Divisions (2)
|
Number |
Date |
Country |
Parent |
767443 |
Dec 1996 |
|
Parent |
266375 |
Jun 1994 |
|